ClinicalTrials.gg
Not yet recruitingNCT07951515Updated Nov 20, 2026

A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Macular Edema After Retinal Vein Occlusion (MK-8748-006)

A Phase 2/3 interventional study of MK-8748 and Aflibercept in Retinal Vein Occlusion and Macular Edema, sponsored by Merck Sharp & Dohme LLC. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-20.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2/3, Interventional, and Treatment

How we know

Updated Nov 20, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
1,188
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Researchers are looking for new ways to treat macular edema after retinal vein occlusion (ME-RVO). ME-RVO happens when a vein becomes blocked in the retina, the back part of the eye. This blockage causes fluid to leak into the macula, which is the part of the retina that helps to see fine details. The buildup of fluid, called macular edema, can cause blurry vision.

In this trial, researchers want to learn if a trial medicine called MK-8748 can treat ME-RVO. A standard (usual) treatment for ME-RVO is aflibercept. However, standard treatments such as aflibercept may not work for every person.

The main goal of this trial is to learn if participants who receive MK-8748 can see as clearly as participants who receive aflibercept.

02

Conditions studied

  • Retinal Vein Occlusion
  • Macular Edema
03

In context

Retinal Vein Occlusion

290 studies on the registry are indexed under Retinal Vein Occlusion; 32 are open to participants now.

This study's planned enrollment of 1,188 is above the median of 51 across 208 interventional studies indexed under Retinal Vein Occlusion.

Browse Retinal Vein Occlusion studies →

Lead sponsor

Merck Sharp & Dohme LLC is the lead sponsor of 2,169 studies on the registry; 134 are open to participants now.

Of its 505 completed or terminated interventional studies of FDA-regulated products, 372 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

The main inclusion criteria include but are not limited to the following:

  • Has a diagnosis of macular edema following retinal vein occlusion (ME-RVO) within 4 months (120 days) before screening and is treatment-naïve for ME-RVO
  • Has a BCVA ETDRS letter score between 73 and 19 (20/40 - 20/400 Snellen equivalent), inclusive, in the study eye at screening. In the event that both eyes are eligible, the worst-seeing eye should be enrolled in the trial.
  • Has a decrease in vision in the study eye determined by the investigator to be primarily the result of ME-RVO.

The main exclusion criteria include but are not limited to the following:

  • Has history of stroke (cerebral vascular accident) or myocardial infarction within 180 days prior to study entry
  • Has any active , except non-melanoma skin carcinoma.
  • Has history of previous episodes of ME-RVO or persistent ME-RVO diagnosed more than 4 months before screening
  • Has any prior implant use including dexamethasone intravitreal implant (Ozurdex®) and fluocinolone acetonide intravitreal implant (Iluvien®) or other intraocular or periocular corticosteroids in the study eye at any time.
  • Has prior periocular pharmacological or intravitreal treatment (including anti-vascular endothelial growth factor medication) for other retinal diseases in the study eye at any time.
  • Has a history of cataract surgery and/or minimally invasive glaucoma surgery in the study eye within 90 days of screening.
  • Has significant active retinal disease (ie, moderate non-proliferative diabetic retinopathy or worse, proliferative diabetic retinopathy, geographic atrophy, myopic choroidal neovascularization) other than the ME-RVO under investigation in the study eye.
  • Is currently using drugs with known retinal toxicity (eg, hydroxychloroquine, pentosan polysulfate sodium).
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
1,188 participants (estimated)

Study arms

  • Experimental
    MK-8748 low dose

    Participants receive MK-8748 low dose every 4 weeks (Q4W) administered in the study eye until week 48. After week 48, participants will be treated at intervals determined based on individualized response to treatment, up to week 96.

    Drug: MK-8748

  • Experimental
    MK-8748 High Dose

    Participants receive MK-8748 high dose every 4 weeks (Q4W) administered in the study eye until week 48. After week 48, participants will be treated at intervals determined based on individualized response to treatment, up to week 96.

    Drug: MK-8748

  • Active comparator
    Aflibercept 2 mg

    Participants receive aflibercept 2 mg every 4 weeks (Q4W) administered in the study eye until week 48. After week 48, participants will be treated at intervals determined based on individualized response to treatment, up to week 96.

    Drug: Aflibercept

Interventions

  • DrugMK-8748

    Administered via intravitreal (IVT) injection

    Also known as: EYE201

  • DrugAflibercept

    Administered via IVT injection

    Also known as: EYLEA

06

What researchers measure

Primary outcomes

  1. Mean Change in Best-Corrected Visual Acuity (BCVA) (Early Treatment of Diabetic Retinopathy Study [ETDRS] Letters) From Baseline to Week 24

    Participants' BCVA in the study eye will be measured using the Early Treatment of Diabetic Retinopathy (ETDRS) methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. Mean change in ETDRS letters from baseline to week 24 will be assessed.

    Time frame: Baseline and Week 24

Secondary outcomes

  1. Mean Change in Central Subfield Thickness (CST) from Baseline to Week 24

    Central subfield thickness (CST) in the study eye will be measured in microns using optical coherence tomography (OCT). The mean change in CST from baseline to week 24 will be presented.

    Time frame: Baseline and Week 24

  2. Mean Change in CST from Baseline Over Time

    Central subfield thickness (CST) in the study eye will be measured in microns using optical coherence tomography (OCT). The mean change in CST from baseline over time will be presented.

    Time frame: Up to approximately 96 weeks

  3. Time to Absence of Diabetic Macular Edema (DME)

    The absence of Diabetic Macular Edema (DME) is defined as a Central Subfield Thickness (CST) of \<300 μm measured using optical coherence tomography (OCT). The time to absence of Diabetic Macular Edema (DME) in the study eye will be presented.

    Time frame: Up to approximately 96 weeks

  4. Proportion of Participants with Absence of Intraretinal Fluid Over Time

    Participants' intraretinal fluid in the study eye will be measured using optical coherence tomography (OCT). The proportion of participants with absence of intraretinal fluid over time will be presented.

    Time frame: Up to approximately 96 weeks

  5. Proportion of Participants with Absence of Subretinal Fluid Over Time

    Participants' subretinal fluid in the study eye will be measured using optical coherence tomography (OCT). The proportion of participants with absence of subretinal fluid over time will be presented.

    Time frame: Up to approximately 96 weeks

  6. Proportion of Participants with Absence of Intraretinal Fluid and Subretinal Fluid Over Time

    Participants' subretinal fluid and intraretinal fluid in the study eye will be measured using optical coherence tomography (OCT). The proportion of participants with absence of intraretinal and subretinal fluid over time will be presented.

    Time frame: Up to approximately 96 weeks

  7. Proportion of Participants with Resolution of Macular Leakage on Fluorescein Angiography (FA) at Week 24

    Fluorescein Angiography (FA) images will be used to determine the resolution of macular leakage in the study eye, defined as 0 to 1 mm\^2. The proportion of participants with resolution of macular leakage at Week 24 will be presented.

    Time frame: Week 24

  8. Proportion of Participants with Resolution of Macular Leakage on FA at Week 48

    FA images will be used to determine the resolution of macular leakage in the study eye, defined as 0 to 1 mm\^2. The proportion of participants with resolution of macular leakage at Week 48 will be presented.

    Time frame: Week 48

  9. Proportion of Participants with Resolution of Macular Leakage on FA at Week 96

    FA images will be used to determine the resolution of macular leakage in the study eye, defined as 0 to 1 mm\^2. The proportion of participants with resolution of macular leakage at Week 96 will be presented.

    Time frame: Week 96

  10. Mean Change in Vascular Leakage Area on FA in the Macula From Baseline Over Time

    Vascular leakage area in the macula will be evaluated using FA images graded by a centralized reading center. The total area of macular vascular leakage will be measured in square millimeters (mm²). The mean change in vascular leakage area from baseline over time will be presented.

    Time frame: Up to approximately 96 weeks

  11. Mean Change From Baseline in Macular Ischemic Nonperfusion Area as Assessed by Optical Coherence Tomography Angiography (OCT-A)

    Macular ischemic nonperfusion area (defined as areas of capillary nonperfusion or capillary drop-out within the superficial and/or deep retinal capillary plexuses) is measured in square millimeters (mm²) using OCT-A. Images are analyzed and graded by a centralized, masked independent reading center. The mean change in ischemic nonperfusion area from baseline over time will be presented.

    Time frame: Up to approximately 96 weeks

  12. Proportion of Participants Requiring Panretinal Photocoagulation

    The proportion of participants requiring panretinal photocoagulation treatment will be presented.

    Time frame: Up to approximately 96 weeks

  13. Mean Number of Intravitreal (IVT) Injections from Week 48 to Week 96

    The mean number of intravitreal (IVT) Injections from week 48 to week 96 will be presented.

    Time frame: Up to approximately 48 weeks

  14. Proportion of Participants on a Personalized Treatment Interval (PTI) of Every 4 Weeks (Q4W) at Week 96

    The proportion of participants on a personalized treatment interval (PTI) of Q4W at Week 96 will be presented.

    Time frame: Up to approximately 96 weeks

  15. Proportion of Participants on a Personalized Treatment Interval (PTI) of Every 8 Weeks (Q8W) at Week 96

    The proportion of participants on a personalized treatment interval (PTI) of Q8W at Week 96 will be presented.

    Time frame: Up to approximately 96 weeks

  16. Proportion of Participants on a Personalized Treatment Interval (PTI) of Every 12 Weeks (Q12W) at Week 96

    The proportion of participants on a personalized treatment interval (PTI) of Q12W at Week 96 will be presented.

    Time frame: Up to approximately 96 weeks

  17. Proportion of Participants on a Personalized Treatment Interval (PTI) of Every 16 Weeks (Q8W) at Week 96

    The proportion of participants on a personalized treatment interval (PTI) of Q16W at Week 96 will be presented.

    Time frame: Up to approximately 96 weeks

  18. Mean Change in BCVA (ETDRS letters) from Baseline Over Time

    Participants' BCVA in the study eye will be measured using the Early Treatment of Diabetic Retinopathy (ETDRS) methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. The mean change in BCVA (ETDRS) letters from baseline over time will be presented.

    Time frame: Baseline and 96 weeks

  19. Proportion of Participants who Gain ≥5 ETDRS Letters from Baseline at Week 24

    Participants' BCVA in the study eye will be measured using the Early Treatment of Diabetic Retinopathy (ETDRS) methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. The proportion of participants who gain ≥5 ETDRS letters from baseline to year 1 will be presented.

    Time frame: Baseline and week 24

  20. Proportion of Participants who Gain ≥10 ETDRS Letters from Baseline at Week 24

    Participants' BCVA in the study eye will be measured using the Early Treatment of Diabetic Retinopathy (ETDRS) methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. The proportion of participants who gain ≥10 ETDRS letters from baseline to year 1 will be presented.

    Time frame: Baseline and week 24

  21. Proportion of Participants who Gain ≥15 ETDRS Letters from Baseline at Week 24

    Participants' BCVA in the study eye will be measured using the Early Treatment of Diabetic Retinopathy (ETDRS) methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. The proportion of participants who gain ≥15 ETDRS letters from baseline to year 1 will be presented.

    Time frame: Baseline and week 24

  22. Proportion of Participants who Gain ≥5 ETDRS Letters from Baseline Over Time

    Participants' BCVA in the study eye will be measured using the Early Treatment of Diabetic Retinopathy (ETDRS) methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. The proportion of participants who gain ≥5 ETDRS letters from baseline over time will be presented.

    Time frame: Up to approximately 96 weeks

  23. Proportion of Participants who Gain ≥10 ETDRS Letters from Baseline Over Time

    Participants' BCVA in the study eye will be measured using the Early Treatment of Diabetic Retinopathy (ETDRS) methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. The proportion of participants who gain ≥10 ETDRS letters from baseline over time will be presented.

    Time frame: Up to approximately 96 weeks

  24. Proportion of Participants who Gain ≥15 ETDRS Letters from Baseline Over Time

    Participants' BCVA in the study eye will be measured using the Early Treatment of Diabetic Retinopathy (ETDRS) methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. The proportion of participants who gain ≥15 ETDRS letters from baseline over time will be presented.

    Time frame: Up to approximately 96 weeks

  25. Proportion of Participants who Lose ≥5 ETDRS Letters from Baseline at Week 24

    Participants' BCVA in the study eye will be measured using the Early Treatment of Diabetic Retinopathy (ETDRS) methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. The proportion of participants who lose ≥5 ETDRS letters from baseline to week 24 will be presented.

    Time frame: Baseline and Week 24

  26. Proportion of Participants who Lose ≥10 ETDRS Letters from Baseline at Week 24

    Participants' BCVA in the study eye will be measured using the Early Treatment of Diabetic Retinopathy (ETDRS) methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. The proportion of participants who lose ≥10 ETDRS letters from baseline to week 24 will be presented.

    Time frame: Baseline and Week 24

  27. Proportion of Participants who Lose ≥15 ETDRS Letters from Baseline at Week 24

    Participants' BCVA in the study eye will be measured using the Early Treatment of Diabetic Retinopathy (ETDRS) methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. The proportion of participants who lose ≥15 ETDRS letters from baseline to week 24 will be presented.

    Time frame: Baseline and Week 24

  28. Proportion of Participants who Lose ≥5 ETDRS Letters from Baseline Over Time

    Participants' BCVA in the study eye will be measured using the Early Treatment of Diabetic Retinopathy (ETDRS) methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. The proportion of participants who lose ≥5 ETDRS letters from baseline over time will be presented.

    Time frame: Up to approximately 96 weeks

  29. Proportion of Participants who Lose ≥10 ETDRS Letters from Baseline Over Time

    Participants' BCVA in the study eye will be measured using the Early Treatment of Diabetic Retinopathy (ETDRS) methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. The proportion of participants who lose ≥10 ETDRS letters from baseline over time will be presented.

    Time frame: Up to approximately 96 weeks

  30. Proportion of Participants who Lose ≥15 ETDRS Letters from Baseline Over Time

    Participants' BCVA in the study eye will be measured using the Early Treatment of Diabetic Retinopathy (ETDRS) methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. The proportion of participants who lose ≥15 ETDRS letters from baseline over time will be presented.

    Time frame: Up to approximately 96 weeks

  31. Proportion of Participants with BCVA Snellen Equivalent of 20/20 or Better at Week 24

    Participants' BCVA in the study eye will be measured using the ETDRS methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. The Snellen equivalent of 20/20 or better is defined as ≥84 letters correctly read in the ETDRS chart. The proportion of participants with BCVA Snellen equivalent of 20/20 or better at week 24 will be presented.

    Time frame: Week 24

  32. Proportion of Participants with BCVA Snellen Equivalent of 20/20 or Better Over Time

    Participants' BCVA in the study eye will be measured using the ETDRS methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. The Snellen equivalent of 20/20 or better is defined as ≥84 letters correctly read in the ETDRS chart. The proportion of participants with BCVA Snellen equivalent of 20/20 or better over time will be presented.

    Time frame: Up to approximately 96 weeks

  33. Proportion of Participants with BCVA Snellen Equivalent of 20/40 or Better at Week 24

    Participants' BCVA in the study eye will be measured using the ETDRS methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. The Snellen equivalent of 20/40 or better is defined as ≥70 letters correctly read in the ETDRS chart. The proportion of participants with BCVA Snellen equivalent of 20/40 or better at week 24 will be presented.

    Time frame: Week 24

  34. Proportion of Participants with BCVA Snellen Equivalent of 20/40 or Better Over Time

    Participants' BCVA in the study eye will be measured using the ETDRS methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. The Snellen equivalent of 20/40 or better is defined as ≥70 letters correctly read in the ETDRS chart. The proportion of participants with BCVA Snellen equivalent of 20/40 or better over time will be presented.

    Time frame: Up to approximately 96 weeks

  35. Proportion of Participants with BCVA Snellen Equivalent of 20/200 or Worse at Week 24

    Participants' BCVA in the study eye will be measured using the ETDRS methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. The Snellen equivalent of 20/200 or worse is defined as ≤38 letters correctly read in the ETDRS chart. The proportion of participants with BCVA Snellen equivalent of 20/200 or worse at week 24 will be presented.

    Time frame: Week 24

  36. Proportion of Participants with BCVA Snellen Equivalent of 20/200 or Worse Over Time

    Participants' BCVA in the study eye will be measured using the ETDRS methodology. The ETDRS letter score ranges from 0 to 100, with a higher score indicating better visual acuity. The Snellen equivalent of 20/200 or worse is defined as ≤38 letters correctly read in the ETDRS chart. The proportion of participants with BCVA Snellen equivalent of 20/200 or worse over time will be presented.

    Time frame: Up to approximately 96 weeks

  37. Change in National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) Version Composite Score Over Time

    The NEI-VFQ-25 is a validated and reliable 25-item survey that measures the influence of visual disability and visual symptoms on generic health domains (emotional well-being, social functioning and task-oriented domains). The composite score ranges from 0-100 with the higher score indicating better visual function. The change in NEI-VFQ-25 version composite score over time will be presented.

    Time frame: Up to approximately 96 weeks

  38. Number of Participants who Experience a Systemic Adverse Event (AE)

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experience a systemic AE will be presented.

    Time frame: Up to approximately 96 weeks

  39. Number of Participants who Experience an Ocular Adverse Event (AE)

    An ocular adverse event (OAE) is defined as any untoward medical occurrence involving the eye or ocular adnexa (including eyelids, conjunctiva, lacrimal apparatus, extraocular muscles, and orbit) that: Occurs or worsens after the first administration of the investigational product (IP) or a study-related ocular procedure, and does not necessarily have a causal relationship with the IP or procedure. OAEs include, but are not limited to, changes in: Symptoms (e.g., ocular pain, photophobia, floaters, blurred vision), Visual function (e.g., best-corrected visual acuity \[BCVA\], visual field). Intraocular pressure (IOP), Anterior segment findings (e.g., conjunctival hyperemia, keratitis, anterior chamber inflammation), Posterior segment findings (e.g., vitreous inflammation, retinal hemorrhages, retinal tears or detachment, macular edema), or ocular adnexa (e.g., eyelid edema, ptosis). The number of participants who experience an ocular AE will be presented.

    Time frame: Up to approximately 96 weeks

  40. Number of Participants who Discontinue Study Treatment Due to an AE

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinue study treatment due to an AE will be reported.

    Time frame: Up to approximately 96 weeks

  41. Number of Participants with Antidrug Antibodies (ADA) to MK-8748

    Blood samples collected at designated timepoints will be used to determine the ADA response to MK-8748. The number of participants with ADA to MK-8748 will be presented.

    Time frame: At designated time points (up to approximately 96 weeks)

  42. Maximum Plasma Concentration (Cmax) of MK-8748

    Cmax is defined as the peak concentration over the dosing interval. Blood samples collected pre-dose and at multiple timepoints post-dose will be used to determine Cmax of MK-8748.

    Time frame: At designated time points (up to approximately 96 weeks)

  43. Plasma Trough Concentration (Ctrough) of MK-8748

    Ctrough is defined as the trough concentration. Blood samples collected pre-dose and at multiple timepoints post-dose will be used to determine Ctrough of MK-8748.

    Time frame: At designated time points (up to approximately 96 weeks)

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Dec 2026; primary completion for Nov 2029, 34 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 16, 2026
First posted
Nov 20, 2026
StartEst.
Dec 21, 2026
Primary completionEst.
Nov 19, 2029
CompletionEst.
Nov 19, 2029
Last update
Nov 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 20, 2026
Show all 1 update
  1. Nov 20, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07951515
Responsible party
Sponsor
First posted
Nov 20, 2026
Start date
Dec 21, 2026 (estimated)
Primary completion
Nov 19, 2029 (estimated)
Completion
Nov 19, 2029 (estimated)
Last update
Nov 20, 2026

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion